FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy …
May 8, 2025 · BOSTON -- (BUSINESS WIRE)--May 8, 2025-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients …
FDA approves Verastem's combo for rare form of ovarian cancer
May 9, 2025 · Verastem is running a confirmatory phase 3 trial, RAMP 301, pitting the combo against standard chemotherapy or hormonal therapy for the treatment of recurrent LGSOC …
US FDA approves Verastem's ovarian cancer therapy | Reuters
May 8 (Reuters) - The U.S. Food and Drug Administration has approved Verastem's (VSTM.O) combination therapy for patients with a rare type of ovarian cancer who have received prior …
FDA Approves Avutometinib-Defactinib Combination for Treating …
May 12, 2025 · The first drug for a rare and difficult-to-treat type of ovarian cancer has been granted accelerated approval by the Food and Drug Administration (FDA). The treatment, …
FDA approves a rare novel–novel oncology combination that …
May 13, 2025 · The FDA has granted accelerated approval to Verastem’s FAK inhibitor defactinib (Fakzynja) in combination with its MEK inhibitor avutometinib (Avmapki) for KRAS-mutated …
FDA Approves New Oral Drug Combo for Rare Ovarian Cancer
May 9, 2025 -- A new oral cancer drug combination has gained a quick federal nod after clinical trials found that it provides significant and longer-lasting relief for a rare ovarian cancer...
FDA Approves First-Ever Drug Combo for Low-Grade Serous Ovarian Cancer
May 9, 2025 · The U.S. Food and Drug Administration (FDA) granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated …
FDA Approves Novel Treatment for KRAS-Mutated Ovarian Cancer …
May 8, 2025 · The US Food and Drug Administration (FDA) has granted accelerated approval of combination avutometinib and defactinib (Avmapki Fakzynja Co-pack, Verastem, Inc.) for the …
FDA approves Verastem Oncology’s combination therapy for …
May 12, 2025 · Avmapki Fakzynja co-pack (avutometinib capsules; defactinib tablets) has been authorised to treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) in …
FDA Grants Accelerated Approval to Verastem Oncology’s …
May 9, 2025 · The FDA has granted accelerated approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack (avutometinib capsules and defactinib tablets). The regulatory action marks …
- Some results have been removed